Okay. Thank you.
In terms of the value, I think you said that pricing would be reduced by about 25% across the board in terms of one of the efficiencies of moving to a national plan, but I noted that the U.S. Veterans Health Administration pays about 50% less than the Canadian public plans pay for generic drugs, and about 40% less than the current Canadian list brands for brand-name drugs.
In terms of that 25%, it looks like another big bulk buying group, smaller even than what Canada would have, with regard to the VA, can get better than 25%. You were just being conservative with that? Or did you have another reason for that 25%?